ProCE Banner Activity

My Take on Strategies to Improve Outcomes in Older Patients with T2D

Clinical Thought

In this expert commentary, Richard E. Pratley, MD gives his perspective on how assessment of comorbidities, individualization of treatment options, ongoing monitoring, and involvement of long-term care facility staff and caregivers to improve patient care can optimize outcomes in older patients with type 2 diabetes (T2D).

Released: September 15, 2022

Expiration: September 14, 2023



Richard E. Pratley

Richard E. Pratley, MD

Samuel E. Crockett Chair in Diabetes Research
Medical Director
AdventHealth Diabetes Institute
Senior Investigator and Diabetes Program Lead
AdventHealth Translational Research Institute
Adjunct Professor of Medicine
Johns Hopkins University School of Medicine
Orlando, Florida


This activity is supported by an educational grant from Sanofi US.


Sanofi US

Target Audience

NPs and PAs that practice in endocrinology


Richard E. Pratley, MD: research support (paid to institution): Hanmi Pharmaceutical Co., Metavention, Novo Nordisk, Poxel SA and Sanofi; consulting fees (paid to institution): Bayer AG, Corcept Therapeutics Incorporated, Dexcom, Gasherbrum Bio, Inc., Hanmi Pharmaceutical Co., Hengrui (USA) Ltd., Merck, Novo Nordisk, Pfizer, Rivus Pharmaceuticals Inc., Sanofi, Scohia Pharma Inc., Sun Pharmaceutical Industries; non-CME/CE services: Novo Nordisk.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose.



Additional Information

Program Medium

This program has been made available online.